PORTLAND, Ore.--(BUSINESS WIRE)--CytoDyn Inc. (“CytoDyn”) (OTC QB: CYDY), a biotechnology company focused on the development of new therapies for combating infection with immune deficiency viruses, announced today that it has entered into a clinical trial agreement with Jeffrey Jacobson, M.D., professor and chief of the Division of Infectious Diseases and HIV Medicine at Drexel University College of Medicine, to conduct additional Phase II studies with PRO 140, an experimental humanized monoclonal antibody (mAb) targeting the CCR5 receptor for the treatment of HIV infection.
